Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Already approved by FDA Oncology. Zenocutuzumab in NRG1+Fusion-Positive Cancer.
A new option for a small subgroup of lung adenocarcinoma (0.2%)- if you test you could find it. | via NEJM.”
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Authors: Alison M. Schram et al.
